Steve Carrell | Authors


Carcinoid Syndrome Symptoms May Improve With Telotristat Etiprate

October 22, 2015

A novel serotonin synthesis inhibitor, telotristat etiprate, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care treatments, an encouraging sign for an emerging class of drugs.

Everolimus Reduces Risk of Progression and Death in Lung/GI NETs

October 20, 2015

Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.

Unprecedented PFS in Midgut NETs Shown With Lu-Dotatate

October 20, 2015

Results from NETTER-1 trial showed an unprecedented 79% reduction in the risk of progression or death with the radiopharmaceutical Lu-Dotatate compared with high-dose octreotide LAR (60 mg) in patients with progressive, metastatic midgut neuroendocrine tumors (NETs).